Study of an eye injection for geographic atrophy
Part of Eyes & vision clinical trials.
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have geographic atrophy (a type of advanced dry age-related macular degeneration) in at least one eye.
- The geographic atrophy spot in the study eye must be at least 0.5 disc areas (about 1.25 mm²) in size.
- No abnormal blood vessel growth (choroidal neovascularization) can be present in the study eye.
- You cannot have a history of recent or active eye inflammation or infection in either eye.
- You cannot have any diabetes-related eye disease (like diabetic retinopathy) in either eye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
This study tests a new gene therapy that may slow or stop the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes vision loss. The treatment is given as an injection into the eye and aims to preserve remaining vision.
This study uses special eye imaging to look closely at areas of damage in the back of the eye (geographic atrophy) caused by age-related macular degeneration. It will help doctors understand early-stage disease better and may guide future treatments.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This trial tests an investigational eye injection (RO7965032) for people with geographic atrophy, a form of dry age-related macular degeneration that causes progressive vision loss. The goal is to see if the treatment can slow further vision loss and preserve sight.
Hear when a new Geographic Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.